Danaher Corporation $DHR Shares Sold by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. trimmed its position in shares of Danaher Corporation (NYSE:DHR) by 9.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 62,015 shares of the conglomerate’s stock after selling 6,638 shares during the period. TD Waterhouse Canada Inc.’s holdings in Danaher were worth $12,020,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Hilton Head Capital Partners LLC purchased a new position in Danaher in the fourth quarter valued at about $27,000. Clal Insurance Enterprises Holdings Ltd increased its stake in Danaher by 71.6% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 127 shares of the conglomerate’s stock valued at $29,000 after purchasing an additional 53 shares during the last quarter. JPL Wealth Management LLC acquired a new stake in Danaher during the third quarter worth about $25,000. N.E.W. Advisory Services LLC acquired a new stake in shares of Danaher during the 2nd quarter worth approximately $25,000. Finally, Main Street Group LTD acquired a new stake in Danaher in the first quarter worth $25,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Performance

Shares of Danaher stock opened at $207.46 on Friday. The stock has a market cap of $145.84 billion, a PE ratio of 36.85, a price-to-earnings-growth ratio of 2.59 and a beta of 0.78. The business has a fifty day simple moving average of $201.74 and a 200-day simple moving average of $192.28. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. The firm had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%.Danaher’s quarterly revenue was up 5.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.77 earnings per share. On average, sell-side analysts anticipate that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on DHR shares. Piper Sandler initiated coverage on Danaher in a research note on Thursday, June 11th. They set a “neutral” rating and a $200.00 target price on the stock. Citigroup started coverage on shares of Danaher in a research note on Tuesday, May 26th. They issued a “buy” rating and a $230.00 price objective on the stock. Stifel Nicolaus reduced their target price on shares of Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a report on Wednesday, July 22nd. DZ Bank began coverage on shares of Danaher in a research report on Wednesday, June 3rd. They issued a “buy” rating and a $210.00 price target on the stock. Finally, Wells Fargo & Company reduced their price objective on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $228.91.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.